Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Wockhardt's current ratio for the quarter that ended in Jun. 2026 was 0.00.
Wockhardt has a current ratio of 0.00. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Wockhardt has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Wockhardt's Current Ratio or its related term are showing as below:
BOM:532300'
s Current Ratio Range Over the Past 10 Years
Min: 0.64 Med: 0.9 Max: 2.6
Current: 1.66
During the past 13 years, Wockhardt's highest Current Ratio was 2.60. The lowest was 0.64. And the median was 0.90.
BOM:532300's Current Ratio is ranked worse than 59.4% of 995
companies
in the Drug Manufacturers industry
Industry Median: 1.93
vs BOM:532300: 1.66
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Wockhardt Current Ratio Related Terms
Wockhardt Current Ratio Historical Data
* Premium members only.
The historical data trend for Wockhardt's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wockhardt Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wockhardt's Current Ratio distribution charts can be found below:
* The bar in red indicates where Wockhardt's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wockhardt (BOM:532300) has a Current Ratio of 0.00 as of Jun. 2026. Over the past decade, Wockhardt's Current Ratio has ranged from 0.64 to 2.60. According to the industry distribution chart, Wockhardt ranks #591 out of 995 companies in the Drug Manufacturers industry, placing it in the top 59.4%.
Is Wockhardt's Current Ratio too high?
Wockhardt's current Current Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 2.60. Based on the distribution chart, Wockhardt ranks #591 out of 995 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Wockhardt has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wockhardt ranks #591 out of 995 companies for Current Ratio. This places Wockhardt in the lower half of its industry. The industry median Current Ratio is 1.93. Historically, Wockhardt's own Current Ratio has ranged from 0.64 to 2.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.93, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current Current Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (BOM:532300) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,465.10, compared to a current price of ₹1,880.25 — trading 28.3% above its estimated fair value. The current Current Ratio is 0.00. Wockhardt's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Wockhardt (BOM:532300), the current Current Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (BOM:532300) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹1,880.25 is trading 28.3% above its estimated GF Value™ of ₹1,465.10.
GuruFocus considers Wockhardt to be Modestly Overvalued.
Key valuation signals for BOM:532300:
Current Ratio: 0.00
GF Value™: ₹1,465.10 vs. price of ₹1,880.25 (28.3% above fair value)
No single metric tells the full story. See the BOM:532300 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
55GF Score
Get the complete analysis for BOM:532300
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532300 has been successfully added to your 
